Entest BioMedical (ENTB) security has been alerted to our Twitter followers after market open as a technical day-trading opportunity. ENTB shares jumped as a high of $.0057 from the $.0032 entry representing 78% in daily gains. Entest BioMedical’s stock traded 3.8 fold of its 10day average volume as of 12:45 EST.
Notice for the ENTB’s investors aka pre-dilution alert:
The Purchase Agreement with Southridge provides that Southridge is committed to purchase up to $10 million of our common stock. We may draw on the facility from time to time, as and when we determine appropriate in accordance with the terms and conditions of the Purchase Agreement.
- Common stock offered by Selling Security Holder 37,640,314 shares of common stock.
- Common stock outstanding before the offering 223,492,927 as of August 9, 2012.
- Common stock outstanding after the offering 261,133,241
Terms of the Offering: The Selling Security Holder will determine when and how it will sell the common stock offered in this prospectus.
Entest BioMedical Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942 USA
Contact: David R. Koos, Chariman and CEO
Company’s areas of focus (besides share selling business):
Immuno-Therapeutic Cancer Vaccine for Canines (Dog Cancer Vaccine)
The first area of focus involves the development of an immuno-therapeutic cancer vaccine for canines. One in every four dogs will develop some sort of cancer during its lifetime. The Company’s goal in this area is to create a treatment that will jumpstart the dog’s own immune system to fight cancer with a device that is in development. Entest BioMedical believes that it will be a “game-changer” for canine oncology.
Veterinary Clinics & Oncology Center Acquisitions
Entest BioMedical sees the acquisition of veterinary clinics and the establishment of a veterinary oncology center as cornerstones to its business model. Veterinary clinics are believed to bring near term revenue to the company, as well as play a strong roll in product distribution as the Company brings products to market.